Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo attack on tough pancreatic cancer shows promise in early trial

NCT ID NCT06831136

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times

Summary

This study tests a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. It combines a procedure that uses heat to destroy tumor cells (radiofrequency ablation) with an immunotherapy drug (pembrolizumab) and standard chemotherapy. The goal is to see if this triple therapy can shrink tumors and improve outcomes. About 24 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Texas Health Science Center at Houston

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.